With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...